STOCK TITAN

Bruker names Eicke Latz to board effective Jan. 1, 2027

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Bruker Corporation (BRKR) will add Eicke Latz, MD, PhD, to its board effective January 1, 2027. The board approved the appointment on November 13, 2026, and expanded the board by one seat to 12 directors; Latz is assigned to Class II and will initially serve until the 2029 Annual Meeting of Stockholders. Latz has co-founded five biotechnology companies and is Scientific Director of the German Rheumatology Research Center and Professor of Experimental Rheumatology at Charité Universitätsmedizin Berlin.

Bruker declared a quarterly cash dividend of $0.05 per share on its common stock. It is payable January 7, 2027, to shareholders of record at the close of business on December 21, 2026.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Quarterly cash dividend $0.05 per share Declared November 12, 2026; payable January 7, 2027, to shareholders of record at the close of business December 21, 2026.
Board size after expansion 12 directors The board approved adding one director.
Biotechnology companies co-founded by Eicke Latz 5 companies Described in the announcement of his board appointment.
innate immunity medical
"discoveries in innate immunity and inflammation"
Innate immunity is the body's first, broad line of defense against infection, made up of cells and chemical signals that recognize and respond quickly to unfamiliar germs without prior exposure — like a security guard and a smoke alarm reacting immediately. For investors, differences in innate immune response shape the market for drugs, vaccines, diagnostics and tests, influence clinical trial outcomes and regulatory reviews, and therefore affect company value and risk.
functional proteomics technical
"AI-accelerated, deep functional proteomics"
Functional proteomics is the study of proteins in cells that focuses on what they do, how they interact, where they act, and how chemical changes alter their behavior. For investors, it matters because it helps reveal which proteins are good drug targets, which biomarkers can track disease or treatment response, and which programs are more likely to succeed — like inspecting not just parts of a machine but how the whole machine runs.
spatial biology technical
"multiomics and spatial biology research"
Spatial biology maps where different cells and molecules sit inside tissues, like a detailed city map showing not just who lives in a neighborhood but where every house and shop is located. For investors, those location details can reveal how diseases start and respond to treatments, guiding new drugs, diagnostics, and lab tools that can change clinical success rates and create commercial opportunities.
molecular diagnostics medical
"next-generation proteomic molecular diagnostics"
Molecular diagnostics are laboratory tests that look for specific molecules — such as genes, pieces of DNA or RNA, or proteins — to detect disease, predict risk, or guide treatment choices. For investors, these tests matter because they can change how illnesses are diagnosed and treated, create recurring revenue through specialized tests and companion products, and face clear regulatory and reimbursement pathways that drive commercial value; think of them as reading a biological barcode to inform medical decisions.
clinical development medical
"programs advancing into clinical development"
Clinical development is the process of testing a medical treatment in people to prove it is safe and works, moving from small early safety checks to larger trials that measure benefit and side effects. For investors it matters because each successful step reduces uncertainty and brings a product closer to regulatory approval and sales—like moving a prototype through road tests before mass production—while failures or delays can dramatically cut expected value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What quarterly dividend did BRKR declare, and when is it payable?

Bruker declared a quarterly cash dividend of $0.05 per share, payable January 7, 2027, to shareholders of record at the close of business on December 21, 2026.

When does Eicke Latz join the BRKR board?

Eicke Latz, MD, PhD, is scheduled to join Bruker’s board effective January 1, 2027. He is assigned to Class II and will initially serve until the 2029 Annual Meeting of Stockholders.

How will Eicke Latz be compensated as a BRKR director?

Bruker stated that Latz’s director compensation will be consistent with that of its other non-employee directors, as described in the company’s definitive proxy statement for the 2026 Annual Meeting of Stockholders.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false00011093540001109354us-gaap:CommonStockMember2026-11-122026-11-1200011093542026-11-122026-11-120001109354brkr:SixPointThreeSevenFivePercentageMandatoryConvertiblePreferredStockSeriesAMember2026-11-122026-11-12

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2026

 

BRUKER CORPORATION

(Exact name of registrant as specified in its charter)

 

 

 

 

 

Delaware

000-30833

04-3110160

(State or other jurisdiction of

(Commission

(I.R.S. Employer

incorporation)

File number)

Identification No.)

 

40 Manning Road

Billerica, MA 01821

(Address of principal executive offices) (Zip Code)

 

(978) 663-3660

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol(s)

Name of Each Exchange on Which Registered

Common Stock, $0.01 par value per share

BRKR

The Nasdaq Global Select Market

6.375% Mandatory Convertible Preferred Stock, Series A, $0.01 par value per share

 

BRKRP

 

 

The Nasdaq Global Select Market

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 


 

Section 5 – Corporate Governance and Management

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

(d) Election of New Director

 

On November 13, 2026, the Board of Directors (the “Board”) of Bruker Corporation (the “Company”) approved an increase in the number of directors to expand the size of the Board by one director to a total of twelve directors, with such additional director assigned to Class II, and appointed Eicke Latz MD PhD to fill the newly created vacancy on the Board, effective as of January 1, 2027. Dr. Latz will initially serve as a director until the 2029 Annual Meeting of Stockholders.

 

Dr. Latz’s compensation for his services as a director will be consistent with that of the other non-employee directors of the Company, as described in the Company’s definitive proxy statement with respect to the 2026 Annual Meeting of Stockholders, filed with the Securities and Exchange Commission on April 10, 2026. There are no other arrangements or understandings between Dr. Latz and any other person pursuant to which he was elected as a director, and Dr. Latz is not a party to any transaction with the Company that would require disclosure under Item 404(a) of Regulation S-K.

 

The Company will file an amended Form 8-K to disclose Dr. Latz’s committee assignments once determined.

A copy of the press release announcing Dr. Latz’s appointment is attached to this report as Exhibit 99.1.

 

Section 8 - Other Events

Item 8.01. Other Events.

The Board declared a quarterly cash dividend on the Company’s common stock, $0.01 par value per share, of $0.05 per share. The dividend was declared on November 12, 2026, and is payable January 7, 2027, to shareholders of record at the close of business on December 21, 2026.

 

Section 9 – Financial Statements and Exhibits

 

Item 9.01. Financial Statements and Exhibits.

 

(d)

Exhibits.

Number

Description

99.1

Press release dated November 16, 2026.

 

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BRUKER CORPORATION
(Registrant)

 Date: November 16, 2026

By:

/s/ THOMAS M. BURES

Thomas M. Bures

Chief Accounting Officer

 

 

 


img53376846_0.jpg

Professor Eicke Latz has co-founded five biotechnology companies, including IFM Therapeutics, Odyssey Therapeutics, Metaimmune Therapeutics, DiosCure Therapeutics, and Beren Therapeutics. His entrepreneurial efforts have focused on translating cutting-edge discoveries in innate immunity and inflammation into novel therapeutic approaches, with programs advancing into clinical development and leading to successful exits and initial public offerings. Through his biopharma ventures, Dr. Latz is bridging fundamental disease biology insights to therapeutic innovation, unmet medical needs and value creation.

 

Eicke Latz

 

 

Exhibit 99.1

 

 

Bruker Announces that Institute Director, Biopharma Entrepreneur and Immunology Leader Dr. Eicke Latz will join its Board of Directors

BILLERICA, Massachusetts – November 16, 2026 – Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors is adding Eicke Latz, MD PhD to serve on its board of directors, effective as of January 1, 2027. Dr. Latz is an internationally recognized medical institute director, physician-scientist, successful biopharma entrepreneur, and innovation leader. His work is transforming the understanding of innate immunity and inflammation, while also advancing numerous therapeutic programs from discovery to clinical development.

Frank H. Laukien, chairman, president and CEO of Bruker Corporation, stated: “Eicke brings a rare combination of world-class disease biology leadership, remarkable biopharma entrepreneurial success, and medical institute strategic leadership to our board. As Bruker expands its leadership in post-genomic life-science tools for disease biology research, molecular diagnostics, and biopharma drug discovery and development, Eicke’s scientific-medical vision, biopharma insights, strategic and leadership experience will be very valuable to Bruker.”

img53376846_1.jpg

 

Dr. Latz is also a highly respected scientific and organizational leader. He is the Scientific Director of the German Rheumatology Research Center (DRFZ) and Professor of Experimental Rheumatology at Charité Universitätsmedizin Berlin, having previously founded and directed the Institute of Innate Immunity at the University of Bonn. His leadership extends across academia medical centers, biopharma industry, and governmental advisory work on venture formation and scaling, to senior advisory roles with major pharmaceutical companies.

“It’s a great honor to join the Board of Directors at Bruker Corporation, a company at the forefront of AI-accelerated, deep functional proteomics, multiomics and spatial biology research,” said Dr. Latz. “I see Bruker as uniquely positioned to enable significant advancements

 


 

in disease biology research, novel biomarker discovery, and next-generation proteomic molecular diagnostics, and I am very excited to contribute.”

About Bruker Corporation – Leader of the Post-Genomic Era

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and semiconductor metrology in support of AI. Bruker offers differentiated, high value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.

Forward-Looking Statements

Any statements contained in this press release which do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those indicated, including, but not limited to, those risk factors discussed from time to time in our filings with the Securities and Exchange Commission, or SEC. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2025, as may be updated by our quarterly reports on Form 10-Q. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by law.

Investor Contact:
Joe Kostka
Director, Investor Relations
Bruker Corporation
T: +1 (978) 313-5800
E:
Investor.Relations@bruker.com
 

 

 

 


Filing Exhibits & Attachments

2 documents

Keep reading